Muscular Treatment Articles & Analysis
4 news found
In the SKYLARK Study, zuranolone was generally well-tolerated, with a safety profile consistent with that observed in the clinical development program to date. The majority of treatment-emergent adverse events (TEAEs) experienced by women in both treatment groups were mild to moderate in severity. ...
Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for major depressive disorder (MDD) and postpartum depression (PPD). ...
An analysis from the ongoing open-label, longitudinal SHORELINE Study in MDD (30 mg cohort n=725, 50 mg cohort n=199) found the median time to the first repeat treatment course for those patients who responded to the initial 14-day treatment course was 135 days for the completed 30 mg cohort (n=489) and 249 days for the ongoing 50 mg cohort (n=146). ...
We expected that approximately 10 patients will be treated each months, according to a treatment protocol written by the hospital’s clinicians together with BioXtreme’s medical advisors. ...